National plans and awareness campaigns as priorities for achieving global brain health.

Neurological conditions are the leading cause of death and disability combined. This public health crisis has become a global priority with the introduction of WHO's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031 (IGAP). 18 months after this plan was adopted, global neurology stakeholders, including representatives of the OneNeurology Partnership (a consortium uniting global neurology organisations), take stock and advocate for urgent acceleration of IGAP implementation. Drawing on lessons from relevant global health contexts, this Health Policy identifies two priority IGAP targets to expedite national delivery of the entire 10-year plan: namely, to update national policies and plans, and to create awareness campaigns and advocacy programmes for neurological conditions and brain health. To ensure rapid attainment of the identified priority targets, six strategic drivers are proposed: universal community awareness, integrated neurology approaches, intersectoral governance, regionally coordinated IGAP domestication, lived experience-informed policy making, and neurological mainstreaming (advocating to embed brain health into broader policy agendas). Contextualised with globally emerging IGAP-directed efforts and key considerations for intersectoral policy design, this novel framework provides actionable recommendations for policy makers and IGAP implementation partners. Timely, synergistic pursuit of the six drivers might aid WHO member states in cultivating public awareness and policy structures required for successful intersectoral roll-out of IGAP by 2031, paving the way towards brain health for all.

Competing Interests: Declaration of interests DW is Chair (unpaid) and CC-B is Vice-Chair (unpaid) of the OneNeurology Partnership. CT has received grants or contracts from ERA-Net Neuron and AbbVie; consulting fees from AbbVie, Eli Lilly, Teva, Pfizer, Lundbeck, and Dompeé; payment or honoraria for lectures or presentations from AbbVie, Eli Lilly, Teva, Pfizer, and Lundbeck; travel support from AbbVie, Eli Lilly, and Lundbeck; and is past president of the International Headache Society. MTF has received consulting fees from Roche, payment or honoraria for lectures or presentations from Lundbeck, and is the co-founder of Women's Brain Project. KR has received consulting fees from Roche (Operetta trial), and payment or honoraria for lectures or presentations from Merck. BMK has received a grant from the National Institute on Aging; royalties or licences from Elsevier; payment or honoraria for lectures and presentations from the American Academy of Neurology, Parkinson's Foundation, International Parkinson and Movement Disorders Society, and Davis Phinney Foundation; and is President of the International Neuropalliative Care Society. CW is an employee of Meningitis Research Foundation, which has received grants from GlaxoSmithKline, Pfizer, Sanofi Pasteur, Serum Institute, and Tableau Foundation. PCZ has received consulting fees from Idorsia, CVS Caremark, Eisai, and Jazz Pharmaceuticals; has stock or stock options in Teva (spouse); and is President of the World Sleep Society. DWD has received consulting fees from Amgen, Atria, CapiThera, Cerecin, Ceruvia Lifesciences, CoolTech, Ctrl M, Allergan, AbbVie, Biohaven, GlaxoSmithKline, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, AYYA Biosciences, Revance, Pfizer, and Perfood; payment or honoraria for lectures or presentations from American Academy of Neurology, Headache Cooperative of the Pacific, Canadian Headache Society, Canadian Pain Society, MF Med Ed Research, Biopharm Communications, CEA Group Holding Company (Clinical Education Alliance), Teva, Amgen, Eli Lilly, Lundbeck, Pfizer, Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin, Medlogix Communications, Medica Communications, MJH Lifesciences, Miller Medical Communications, WebMD Health/Medscape, Wolters Kluwer, Oxford University Press, and Cambridge University Press; has non-profit board membership with American Brain Foundation, American Migraine Foundation, OneNeurology, International Headache Society Global Patient Advocacy Coalition, Atria Health Collaborative, Arizona Brain Injury Alliance, and Domestic Violence HOPE Foundation/Panfila; has received financial support from the Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, and Patient Centered Outcomes Research Institute; has stock options in Aural Analytics, ExSano, Palion, Man and Science, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, Ontologics, King-Devick Technologies, EigenLyfe, AYYA Biosciences, Cephalgia Group, and Atria Health; has shares in Axon Theraputics, Ontologics, EigenLyfe, and Cephalgia Group; is on the board of directors for Axon Theraputics, King-Devick Technologies, and Cephalgia Group; and has the following patent (number 17189376.1-1466; Title: Onabotulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis (non-royalty bearing); patent application submitted: Synaquell (Precon Health). AH is an employee of Multiple Sclerosis International Federation (MSIF); MSIF received funding from BristolMyersSquibb, Sanofi, Merck, Viatris (formerly Mylan), Novartis, Biogen, and Roche over the last 5 years. MSIF's independence and all its donations from the health-care industry are governed by MSIF's health-care policy. MSIF has not received any funding from industry for its access to medicines work in 2019, 2020, 2021, 2022, or 2023. JL-D was an employee at MSIF until October, 2023. OG and TH received institutional support from the European Federation of Neurological Associations in running the OneNeurology Secretariat. All other authors declare no competing interests.

(Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)